" class="no-js "lang="en-US"> Accord Healthcare Adds Generic Drug for Use in Treating Leukemia and Non-Hodgkin's Lymphoma - Medtech Alert
Thursday, May 23, 2024

Accord Healthcare Adds Generic Drug for Use in Treating Leukemia and Non-Hodgkin’s Lymphoma

Accord Healthcare, a leading generic pharmaceutical company, has added Bendamustine Lyo Injection to its line of chemotherapy drugs to treat Leukemia and Non-Hodgkin’s Lymphoma. Accord’s product is AP rated to Teva’s Treanda® and is being offered in both 25-mg and 100-mg vials.

Bendamustine Lyo. Injection is in a class of medications called alkylating agents1. It works by killing existing cancer cells and limiting the growth of new cancer cells. Bendamustine is indicated for the treatment of adults with chronic lymphocytic leukemia (CLL) or indolent B-cell non-Hodgkin’s lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or rituximab containing regimen.

“Adding Bendamustine Lyo. Injection to our line of available chemotherapy drugs is an important step in continuing to make oncology therapies more accessible to those who need them,” said Accord Healthcare President Jeff Hampton. “The availability of generics expands medication options for patients. When pharmacists have access to additional manufacturers, they are able to offer needed oncology products at a lower cost.”

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more